Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 4/20 | 0.46 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CYCS | P99999 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14572001 | 0.88 | HTR7 (0.39) | TERT | |
| SCHEMBL1410106 | 0.80 | TERT (0.43) | TERTTOP1ABCG2CYCS | |
| SCHEMBL9998554 | 0.79 | TERT (0.36) | TERTTOP1ABCG2CYCS | |
| SCHEMBL12836952 | 0.73 | KDM4E (0.36) | TERTTOP1ABCG2CYCS | |
| SCHEMBL7717047 | 0.72 | TERT (0.37) | TERTTOP1 | |
| Hydrochloric Acid SCHEMBL1409803 | 0.71 | TERT (0.49) | TERTTOP1CYCS | |
| SCHEMBL1409926 | 0.70 | TOP1 (0.44) | TERTTOP1ABCG2CYCS | |
| SCHEMBL29869092 | 0.70 | TERT (0.49) | TERTTOP1CYCS | |
| SCHEMBL448020 | 0.70 | TERT (0.49) | TERTTOP1CYCS | |
| SCHEMBL17018807 | 0.70 | KDM4E (0.38) | TERTTOP1ABCG2CYCS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333019-A1 | SYNTHESIS AND FORMULATIONS OF PORPHYRIN COMPOUNDS | AEOLUS SCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333019-A1 | SYNTHESIS AND FORMULATIONS OF PORPHYRIN COMPOUNDS | AEOLUS SCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| US-7189707-B2 | Substituted porphyrins | NATIONAL JEWISH MEDICAL RESEARCH CENTER (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1616869-A1 | Substituted porphyrins and their therapeutic use | National Jewish Medical and Research Center (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1155019-B1 | SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE | NAT JEWISH MED & RES CENTER (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-02-05 | — | — | US | disclosed |
| US-6544975-B1 | Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333019-A1 | SYNTHESIS AND FORMULATIONS OF PORPHYRIN COMPOUNDS | PPOX, HMBS, COX15 | TERT 1425/4885TOP1 1701/4885ADRA2A 4574/4885 |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885ADRA2A 4330/4885 |
| US-20040023941-A1 | Modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and | TXN2, PRDX5, GPX4 | TERT 2424/4885TOP1 4748/4885ADRA2A 1871/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | TERT 771/4885TOP1 3334/4885ADRA2A 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.